BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 27, 2006
 |  BioCentury  |  Strategy

The sum greater than the whole

It isn't uncommon for a company to have enough cash to develop a lead product but not enough to shepherd the rest of its pipeline. The danger is that the cash-strapped entity ends up being acquired by a company that keeps the lead and shuts down everything else. To avoid that fate, IDEA AG last week opted to split itself into two parts.

Under a deal with its most recent and largest investor, IDEA (Munich, Germany) will offload its Transfersome drug delivery platform in order to focus on its Phase III compound for pain. The rest of the company will be put into TDT, a subsidiary of private equity firm Celtic Pharmaceutical Holding LP (Hamilton, Bermuda).

"We wanted to secure a long-term perspective for our technology, the staff, and the portfolio, so we explored several opportunities," CEO Gregor Cevc told BioCentury.

One possibility was to follow the route of Micromet AG (Munich, Germany). In January, it formed Micromet Inc. (proposed: MITI, Carlsbad, Calif.) in the U.S. through a reverse merger with CancerVax Corp. (CNVX, Carlsbad, Calif.) (see BioCentury, Jan. 16).

"We started looking into this nearly two...

Read the full 932 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >